Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Other Non-Current Assets (2016 - 2025)

IGC Pharma (IGC) has disclosed Other Non-Current Assets for 15 consecutive years, with $672000.0 as the latest value for Q3 2025.

  • Quarterly Other Non-Current Assets fell 2.18% to $672000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $672000.0 through Sep 2025, down 2.18% year-over-year, with the annual reading at $681000.0 for FY2025, 1.02% down from the prior year.
  • Other Non-Current Assets for Q3 2025 was $672000.0 at IGC Pharma, down from $680000.0 in the prior quarter.
  • The five-year high for Other Non-Current Assets was $1.0 million in Q4 2022, with the low at $18000.0 in Q2 2021.
  • Average Other Non-Current Assets over 5 years is $534888.9, with a median of $676000.0 recorded in 2025.
  • The sharpest move saw Other Non-Current Assets skyrocketed 5022.22% in 2022, then tumbled 97.37% in 2023.
  • Over 5 years, Other Non-Current Assets stood at $612000.0 in 2021, then soared by 67.97% to $1.0 million in 2022, then crashed by 97.37% to $27000.0 in 2023, then skyrocketed by 2422.22% to $681000.0 in 2024, then dropped by 1.32% to $672000.0 in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $672000.0, $680000.0, and $681000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.